NASDAQ: CAICaris Life Sciences Inc Stock
$17.31-1.16 (-6.28%)
Updated Jun 22, 2026
CAI Price
$17.31
Fair Value Price
-$15.86
Market Cap
$4.89B
52 Week Low
$14.19
52 Week High
$42.50
P/E
-2.76x
P/B
8.24x
P/S
5.57x
PEG
N/A
Dividend Yield
N/A
Revenue
$907.29M
Earnings
$33.98M
Gross Margin
68.7%
Operating Margin
10%
Profit Margin
-45.3%
Debt to Equity
0.96
Operating Cash Flow
$147M
Beta
1.54
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CAI Overview
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CAI's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CAI
Ranked#71 of 467
Ranked#71 of 467
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $225.92 | A | |
| $51.35 | A | |
| $2.16 | A |
Be the first to know about important CAI news, forecast changes, insider trades & much more!
CAI News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CAI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CAI ($17.31) is overvalued by 209.14% relative to our estimate of its Fair Value price of -$15.86 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CAI ($17.31) is not significantly undervalued (209.14%) relative to our estimate of its Fair Value price of -$15.86 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CAI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CAI due diligence checks available for Premium users.
Valuation
CAI fair value
Fair Value of CAI stock based on Discounted Cash Flow (DCF)
Price
$17.31
Fair Value
-$15.86
Undervalued by
209.14%
CAI ($17.31) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CAI ($17.31) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CAI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CAI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.76x
Industry
15.1x
Market
7.94x
CAI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
8.24x
Industry
5.1x
CAI is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CAI's financial health
Profit margin
Revenue
$216.2M
Net Income
-$510.0k
Profit Margin
-0.2%
CAI's Earnings (EBIT) of $90.73M... subscribe to Premium to read more.
Interest Coverage Financials
CAI's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.2B
Liabilities
$568.9M
Debt to equity
0.96
CAI's short-term assets ($1.01B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CAI's short-term assets ($1.01B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CAI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$32.9M
Investing
-$10.3M
Financing
$824.0k
CAI's operating cash flow ($147.37M)... subscribe to Premium to read more.
Debt Coverage Financials
CAI vs Biotech Stocks
Caris Life Sciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.